Sponsor-Investigators

Kari Wisinski

BTCRC-BRE15-024

A phase I/II, single arm, non-randomized study of ribociclib (LEE011), a CDK 4/6 inhibitor in combination with bicalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-024

Status

Cancer Types

Breast

Locations

University of Illinois Cancer Center, University of Rochester Medical Center - Wilmot Cancer Institute, University of Wisconsin Carbone Cancer Center

BTCRC-BRE18-337

Phase 2 Trial With Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers: Big Ten Cancer Research Consortium BTCRC-BRE18-337

Status

Open to Accrual

Cancer Types

Breast

Locations

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, University of Illinois Cancer Center, University of Iowa Holden Comprehensive Cancer Center, University of Wisconsin Carbone Cancer Center